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https://doi.org/10.1016/j.molcel.2020.12.012SUMMARYAerobic glycolysis, or preferential fermentation of glucose-derived pyruvate to lactate despite available
oxygen, is associated with proliferation across many organisms and conditions. To better understand that
association, we examined the metabolic consequence of activating the pyruvate dehydrogenase complex
(PDH) to increase pyruvate oxidation at the expense of fermentation. We find that increasing PDH activity im-
pairs cell proliferation by reducing the NAD+/NADH ratio. This change in NAD+/NADH is caused by increased
mitochondrial membrane potential that impairs mitochondrial electron transport and NAD+ regeneration.
Uncoupling respiration from ATP synthesis or increasing ATP hydrolysis restores NAD+/NADH homeostasis
and proliferation even when glucose oxidation is increased. These data suggest that when demand for NAD+
to support oxidation reactions exceeds the rate of ATP turnover in cells, NAD+ regeneration bymitochondrial
respiration becomes constrained, promoting fermentation, despite available oxygen. This argues that cells
engage in aerobic glycolysis when the demand for NAD+ is in excess of the demand for ATP.INTRODUCTION
Cell growth and division impose increased energetic and biosyn-
thetic demands, and thus, proliferating cells exhibit a distinct
metabolism relative to non-proliferating cells. Under aerobic
conditions, most cells reduce oxygen to water via respiration
to support the oxidation reactions used to derive energy from
nutrients. When oxygen is limiting, cells instead ferment carbo-
hydrates to generate awaste product, such as lactate or ethanol,
as an alternative, less carbon efficient way to derive energy from
nutrients. However, some cells, including many rapidly prolifer-
ating cells, exhibit high rates of fermentation, even when oxygen
is abundant, a metabolic phenotype known as aerobic glycol-
ysis. Aerobic glycolysis has been associated with tumors (Kop-
penol et al., 2011; Warburg, 1924, 1956), but this phenotype is
not unique to cancer. Aerobic glycolysis is exhibited by some
proliferating microorganisms, including species of yeast andMolecular Cell 81, 691–707, Feb
This is an open access article under the CC BY-Nbacteria, and many proliferating non-transformed mammalian
cells, including lymphocytes and fibroblasts (Brand et al.,
1986; Hume et al., 1978; Lemoigne et al., 1954; Munyon and
Merchant, 1959; Wang et al., 1976). Select non-proliferative
cells, such as pigmented epithelial cells of themammalian retina,
also engage in aerobic glycolysis (Chinchore et al., 2017; Krebs,
1927). Despite being a phenotype found in many different cells
and organisms, what drives aerobic glycolysis andwhy it is asso-
ciated with proliferation has never been fully explained (Liberti
and Locasale, 2016).
Aerobic glycolysis produces less ATP per mole of glucose
than does complete glucose oxidation to CO2, raising the ques-
tion of why some cells engage in ametabolic program that is less
efficient with respect to ATP generation (Koppenol et al., 2011;
Liberti and Locasale, 2016; Vander Heiden et al., 2009). This
paradox is particularly apparent in cancer and led to the hypoth-
esis that tumors have defects in mitochondrial respirationruary 18, 2021 ª 2020 The Authors. Published by Elsevier Inc. 691
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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caused by tumor-associated hypoxia (Gatenby and Gillies,
2004); however, aerobic glycolysis is a feature of many cells
without a precedent oxygen limitation (Vander Heiden et al.,
2009). Tumors also retain functional mitochondria (Koppenol
et al., 2011;Weinhouse, 1956) and require mitochondrial respira-
tion for growth, progression, and metastasis (LeBleu et al., 2014;
Tan et al., 2015; Viale et al., 2014; Weinberg et al., 2010). Collec-
tively, these findings argue against mitochondrial damage or
oxygen limitation as the primary driver of this phenotype.
Furthermore, it is a common misconception that aerobic glycol-
ysis involves suppression of oxidative phosphorylation (Yao
et al., 2019). Aerobic glycolysis is best characterized by
increased fermentation with continued respiration, resulting in
a shift in metabolism in which more glucose is fermented relative
to that which is oxidized.
Several other models have been proposed to explain why aer-
obic glycolysis is observed in proliferating cells. One is that
increased flux through glycolysis can shunt biosynthetic precur-
sors into anabolic reactions that branch from this pathway,
contributing to production of nucleosides, lipids, and/or proteins
(Boroughs and DeBerardinis, 2015; Cairns et al., 2011; Hume
and Weidemann, 1979; Levine and Puzio-Kuter, 2010; Vander
Heiden et al., 2009). Although the idea that inefficient ATP pro-
duction is a trade-off for supporting anabolic reactions is attrac-
tive, glycolytic intermediates are not necessarily elevated in
proliferating cells (Lunt et al., 2015; Williamson et al., 1970),
and many proliferating cells excrete the majority of consumed
glucose carbons as lactate. In fact, amino acids, rather than
glucose, account for most new carbon biomass in proliferating
cells (Hosios et al., 2016). Another proposed benefit of the
Warburg effect is increased ATP production because ATP can
be generated with faster kinetics by aerobic glycolysis than it
can by oxidative phosphorylation (Pfeiffer et al., 2001). It has
also been suggested that aerobic glycolysis arises because of
constraints on metabolism caused by molecular crowding (Vaz-
quez et al., 2010; Vazquez and Oltvai, 2011) or that the energetic
cost of synthesizing glycolytic enzymes is less than that of syn-
thesizing components needed for respiration, such that ATP pro-
duction by glycolysis confers a fitness advantage to cells (Basan
et al., 2015). Nevertheless, why aerobic glycolysis is engaged in
some, but not all, rapidly proliferating cells is not fully explained
by existing models.
The end product of glycolysis is pyruvate, which can be fer-
mented to lactate or further oxidized by a series of reactions
that depend on mitochondrial respiration, in which electrons
released by glucose oxidation are disposed of via the reduction
of oxygen to water. The first step in pyruvate oxidation is cata-
lyzed by the pyruvate dehydrogenase complex (PDH), which
converts pyruvate to acetyl coenzyme A (acetyl-CoA) in a reac-
tion that is irreversible under physiological conditions. PDH ac-
tivity is suppressed by a low NAD+/NADH ratio (Pettit et al.,
1975) and regulated further by pyruvate dehydrogenase kinases
(PDKs) and pyruvate dehydrogenase phosphatases (PDPs),
which modulate PDH by inhibitory phosphorylation (Kolobova
et al., 2001; Korotchkina and Patel, 2001). Thus, PDH regulation
influences the extent to which cells engage in aerobic glycolysis
(Grassian et al., 2011; Kim et al., 2006; Papandreou et al., 2006).692 Molecular Cell 81, 691–707, February 18, 2021Activation of PDH, either by PDK inhibition or PDP activation,
suppresses aerobic glycolysis and can slow cancer cell prolifer-
ation and tumor growth (Hitosugi et al., 2011; Kaplon et al., 2013;
McFate et al., 2008).
To investigate how aerobic glycolysis supports cell prolifera-
tion, we studied the consequence of suppressing fermentation
in cells by increasing PDH activity. We find that promoting pyru-
vate oxidation impairs cell proliferation by limiting NAD+ avail-
ability for oxidation reactions because interventions that regen-
erate NAD+ restore proliferation despite PDH activation. We
further find that the reduced NAD+/NADH ratio in those cells re-
sults from increased mitochondrial membrane potential that im-
pedes NAD+ regeneration by mitochondrial electron transport.
Uncoupling electron transport frommitochondrial ATP synthesis
relieves the increased mitochondrial membrane potential and in-
creases NAD+ regeneration via respiration. Furthermore,
increasing cellular ATP consumption rescues proliferation
when PDH is activated, suggesting that ATP synthase insuffi-
ciency can be an endogenous constraint on NAD+ regeneration
by coupledmitochondrial respiration. Lastly, endowing cells with
alternative means of NAD+ regeneration suppresses aerobic
glycolysis in both mammalian and yeast cells, without affecting
the proliferation rate. These data argue that cells engage in
aerobic glycolysis when the NAD+ demand for oxidation reac-
tions exceeds the demand for ATP, creating a situation in
which mitochondrial respiration is insufficient to support NAD+
regeneration.
RESULTS
PDK inhibition activates PDH, suppressing aerobic
glycolysis and cell proliferation
To better understand why proliferating cells engage in aerobic
glycolysis, we sought to suppress this phenotype by increasing
glucose oxidation relative to fermentation. Flux through PDH, the
first committed step for mitochondrial glucose oxidation, is
negatively regulated by PDK, and PDK inhibition can suppress
aerobic glycolysis in various contexts (Hitosugi et al., 2011; Ka-
plon et al., 2013; McFate et al., 2008; Michelakis et al., 2010). We
used AZD7545, a potent and selective inhibitor of PDK1, PDK2,
and PDK3 (Kato et al., 2007; Morrell et al., 2003), to promote py-
ruvate oxidation (Figure 1A). Exposing cancer cells to AZD7545
decreased inhibitory phosphorylation of the E1a subunit of
PDH (Figure 1B), confirming functional PDK inhibition by this
small molecule. We next assessed PDH activity in cells with
and without PDK inhibition by measuring incorporation of car-
bons from 13C-labeled glucose into citrate.We observed kinetics
consistent with elevated PDH activity in cells treated with
AZD7545 at multiple concentrations (Figures 1C and S1A). Oxy-
gen consumption rate (OCR) was also increased upon AZD7545
treatment in some, but not all, cells examined (Figures 1D and
S1B). However, AZD7545 treatment decreased the rate of
lactate excretion per glucose molecule consumed in all tested
cells (Figure 1E), confirming that PDK inhibition increases PDH
activity, promoting pyruvate oxidation at the expense of fermen-
tation, which represents a shift away from aerobic glycolysis.
We next tested the effects of AZD7545 on cell proliferation
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myoblasts, and primary murine pancreatic stellate cells (PSCs)
(Figure 1G). AZD7545 also suppressed proliferation of activated
primary human CD4+ T cells and primary mouse T cells (Figures
1H, 1I, S1C, and S1D) but had minimal effect on the expression
of T cell activation markers (Figure S1E). These data demon-
strate that PDH activation impairs proliferation in both cancer
and non-cancer settings.
To confirm that AZD7545 inhibits cell proliferation as a result of
PDK inhibition, rather than another effect of this compound, we
disrupted PDK1 expression in 143B cells using CRISPR interfer-
ence (CRISPRi) (Figure S1F) and found that genetic PDK1 sup-
pression slowed cell proliferation (Figure 1J). Furthermore, high
PDH activity is selected against for tumor growth in mice
because 143B cells with PDK1 knockdown displayed impaired
tumor formation relative to control cells (Figure 1K). Of note,
when PDK1 knockdown cells formed tumors, some of those
tumors grew at a rate similar to tumors derived from control cells
(Figure S1G); however, tumors derived from PDK1 knockdown
cells regained PDK1 expression (Figure 1L). Furthermore, control
and PDK1 knockdown tumors expressed higher levels of PDK1
than did the cells from which they were derived (Figure 1L).
Taken together, these data are consistent with numerous studies
showing enhanced PDH activation specifically (Kaplon et al.,
2013;McFate et al., 2008;Michelakis et al., 2010), and suppress-
ing aerobic glycolysis more generally (Fantin et al., 2006; Le
et al., 2010; Xie et al., 2014) can slow cell proliferation and tumor
growth.
PDH activation decreases proliferation by decreasing
the NAD+/NADH ratio in cells
Understanding how increased pyruvate oxidation suppresses
cell proliferation could provide insight into why proliferating cells
engage in aerobic glycolysis. One potential explanation is thatFigure 1. Activation of PDH suppresses aerobic glycolysis and prolifer
(A) Pyruvate has several fates in cells, including metabolism to lactate by lactate d
CoA for entry into the tricarboxylic acid (TCA) cycle. PDH is negatively regulated
compound AZD7545.
(B) Western blot to assess S293 phosphorylation of the PDH-E1a enzyme subuni
PDH-E1a expression was also assessed.
(C) Kinetic labeling of citrate from 13C-labeled glucose to assess PDH flux with
incubated for 5 h in medium containing 5 mM unlabeled glucose with vehicle or 0.5
M+2 citrate was measured by liquid chromatography-mass spectrometry (LCMS
(D) Oxygen consumption rate (OCR) of cells treated with vehicle or 0.5 mM AZD7
(E) Lactate excretion into culture medium normalized to glucose consumption of
(F) Proliferation rate of 143B, H1299, and HeLa cells treated with vehicle or AZD
(G) Proliferation rate of C2C12 myoblasts or mouse pancreatic stellate cells (PSC
(H) Proliferation of primary human CD4+ T cells cultured in vehicle or 5 mM AZD7
nimidyl ester) before stimulation with anti-CD3/CD28 Dynabeads, and CFSE fluor
shown from three biological replicates of primary human CD4+ T cells collecte
unstimulated cells (light gray) that did not proliferate are also shown.
(I) Proliferation of primary mouse T cells cultured in vehicle or 5 mM AZD7545. M
antibodies, and CFSE fluorescence was assessed by flow cytometry after 2 days
(J) Proliferation rate of 143B cells in which CRISPR interference (CRISPRi) was us
(sgRNA) targeting PDK1 (two independently targeted lines) or a non-targeting co
(K) Histogram indicating the number of weeks at which the cell lines described in
(L) Western blot analysis to assess PDK1 expression in the cells shown in (J) when
after 34 days.
Values in (C)–(G), and (J) denote means ± SD. p values were calculated by unpa
694 Molecular Cell 81, 691–707, February 18, 2021altering the ratio of glucose oxidation to lactate fermentation
can affect the oxidative capacity of cells. The NAD+/NADH ratio
is critical for many metabolic reactions, including those involved
in central carbon metabolism, nucleotide synthesis, lipid meta-
bolism, and amino acid metabolism (Hosios and Vander Heiden,
2018), andNAD+ regeneration can be limiting for cell proliferation
and tumor growth (Birsoy et al., 2015; Gui et al., 2016; Sullivan
et al., 2015; Titov et al., 2016). The reaction catalyzed by PDH
consumes NAD+ to produce NADH, and shunting pyruvate
away from lactate production prevents NAD+ regeneration by
lactate dehydrogenase (LDH) (Figure 2A). Thus, PDK inhibition
is expected to favor a more reduced NAD+/NADH ratio, and
indeed, AZD7545 treatment lowered the NAD+/NADH ratio in
cells (Figures 2B and S2A).
We next questionedwhether sensitivity to PDK inhibition could
be changed by altering the intracellular NAD+/NADH ratio.
Pyruvate is rapidly reduced by LDH, and providing exogenous
pyruvate increases the NAD+/NADH ratio in cells (Birsoy et al.,
2015; Gui et al., 2016; Sullivan et al., 2015). We found that
pyruvate supplementation restored the NAD+/NADH ratio in
AZD7545-treated cancer cells (Figure 2C), enhanced baseline
cell proliferation, and suppressed the anti-proliferative effects
of AZD7545 and of the genetic suppression of PDK1 (Figures
2D, 2E, and S2B). Pyruvate also increased the proliferation of
non-transformed C2C12 myoblasts and primary mouse PSCs
treated with AZD7545 (Figure 2F), as well as of activated primary
human CD4+ T cells (Figures 2G, S2C, and S2D) and primary
mouse T cells (Figures 2H, S2E, and S2F). These data argue
that exogenous pyruvate suppresses the anti-proliferative
effects of PDH activation.
Lactate can serve as a nutrient for cells, including cancer cells
(Faubert et al., 2017; Hui et al., 2017; Kennedy et al., 2013; Son-
veaux et al., 2008). Lactate metabolism first requires conversion
to pyruvate, serving as an electron donor for the LDH reactionation
ehydrogenase (LDH) or oxidation by pyruvate dehydrogenase (PDH) to acetyl-
by pyruvate dehydrogenase kinase (PDK) enzymes, which are inhibited by the
t in HeLa, 143B, and H1299 cells treated with vehicle or AZD7545 for 2 h. Total
and without PDK inhibition by AZD7545. HeLa, 143B, and H1299 cells were
mMAZD7545; after which, 20 mM [U-13C6]glucose was added. The fraction of
) after the addition of 13C-labeled glucose (n = 3).
545 for 5 h (n = 4).
cells treated with vehicle or 0.25 mM AZD7545 for 48 h (n = 5).
7545, as indicated (n = 3).
s) cultured in vehicle or AZD7545 as indicated (n = 3).
545. Human CD4+ T cells were stained with CFSE (carboxyfluorescein succi-
escence was assessed by flow cytometry after 4 days. Representative data are
d from different donors and analyzed as independent experiments. Stained,
ouse T cells were stained with CFSE before stimulation with anti-CD3/CD28
. Stained, unstimulated cells (light gray) that did not proliferate are also shown.
ed to repress PDK1 expression. Cells were transduced with single-guide RNA
ntrol (NTC) as indicated (n = 3).
(J) formed xenograft tumors larger than 50 mm3 in nude mice (n = 15).
cultured in vitro (TC) or after being isolated from the xenografts described in (K)








Figure 2. PDK inhibition slows cell proliferation by reducing the NAD+/NADH ratio
(A) PDK inhibition by AZD7545 decreases the NAD+/NADH ratio by promoting flux through NAD+-consuming pathways, including PDH and the TCA cycle and by
limiting pyruvate conversion to lactate by LDH.
(B) The NAD+/NADH ratio of 143B and H1299 cells cultured in vehicle or 5 mM AZD7545 for 5 h (n = 4).
(C) The NAD+/NADH ratio of 143B and H1299 cells treated with vehicle, 5 mM AZD7545, or 5 mM AZD7545 with 1 mM pyruvate (n = 4).
(D) Proliferation rate of 143B andH1299 cells cultured in vehicle (V) or the indicated concentration of AZD7545 in the presence (dark blue) or absence (light blue) of
1 mM pyruvate (n = 3).
(legend continued on next page)
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OPEN ACCESS Articlethat converts NAD+ to NADH (Figure 2A), and exogenous lactate
further decreased the NAD+/NADH ratio of AZD7545-treated
cells (Figures 2I and S2G). Exogenous lactate also suppressed
cell proliferation and exacerbated the effect of AZD7545 treat-
ment in 143B and H1299 cells (Figure 2J), but not HeLa cells (Fig-
ure S2H). Altering extracellular lactate relative to extracellular py-
ruvate can titrate the cellular NAD+/NADH ratio (Hung et al.,
2011), and we found that lower extracellular lactate to pyruvate
ratios suppressed the ability of AZD7545 to impair proliferation
(Figure S2I). These data support NAD+ depletion as an explana-
tion for why increasing pyruvate oxidation slows proliferation.
Tomore directly test whether changes in the NAD+/NADH ratio
mediate the anti-proliferative effects of PDK inhibition, we tested
whether orthogonal pathways that regenerate NAD+, but are not
involved in glucose, pyruvate, or lactate metabolism, affect
sensitivity to AZD7545. Duroquinone permits NAD+ regeneration
via the quinone reductase NQO1 (Merker et al., 2006) (Figure 3A),
and duroquinone raises the NAD+/NADH ratio and can rescue
cell proliferation in conditions in which NAD+ is limiting (Gui
et al., 2016). We found that duroquinone suppressed AZD7545
sensitivity (Figures 3B and S3A), consistent with a decreased
NAD+/NADH ratio slowing proliferation of PDK-inhibited cells.
Another orthogonal method for increasing the cell NAD+/
NADH ratio is expressing NADH oxidase from Lactobacillus bre-
vis (LbNOX) (Titov et al., 2016) (Figure 3C). Thus, we engineered
cells to express either LbNOX or an empty vector (E.V.) as
another way to assess the effect of increasing NAD+ regenera-
tion in cells (Figure S3B). LbNOX expression conferred resis-
tance to the anti-proliferative effects of AZD7545 (Figures 3D
and S3C), further demonstrating that increasing NAD+ regenera-
tion can permit rapid proliferation despite increased pyruvate
oxidation.Changes in NAD+/NADH account for how PDH activation
affects cell metabolism
NAD+ is necessary to support oxidation reactions in cells, and
thus, changes in the NAD+/NADH ratio impacts many metabolic
pathways, including those important for cell growth and prolifer-
ation (Hosios and Vander Heiden, 2018). For example, the NAD+/
NADH ratio can affect aspartate synthesis (Birsoy et al., 2015;
Sullivan et al., 2015). Aspartate is essential in making proteins,
as well as purine and pyrimidine nucleotides, and acquiring
aspartate can be limiting for tumor growth (Garcia-Bermudez
et al., 2018; Rabinovich et al., 2015; Sullivan et al., 2018).(E) Proliferation rate of 143B cells in which CRISPRi was used to repress PDK1. C
and grown in the presence or absence of 1 mM pyruvate (n = 3).
(F) Proliferation rate of C2C12 myoblasts and pancreatic stellate cells (PSCs) in m
(n = 3).
(G) Proliferation of primary human CD4+ T cells treated with 5 mM AZD7545 with o
stimulation with CD3/CD28 Dynabeads, and CFSE fluorescence was assessed
biological replicates of primary human CD4+ T cells collected from different dono
gray) that did not proliferate are shown.
(H) Proliferation of primarymouse T cells treatedwith 5 mMAZD7545with or withou
anti-CD3/CD28 antibodies. CFSE fluorescence was assessed by flow cytometr
are shown.
(I) The NAD+/NADH ratio of 143B and H1299 cells cultured in vehicle, 5 mM AZD
(J) Proliferation rate of 143B and H1299 cells treated with vehicle (V) or AZD7545
Values in (B)–(F), (I), and (J) denote means ± SD. p values were calculated by un
696 Molecular Cell 81, 691–707, February 18, 2021Therefore, to determine whether one method by which PDK inhi-
bition impairs proliferation is by affecting aspartate availability,
we measured aspartate levels in cells cultured in the presence
of vehicle or AZD7545. Consistent with AZD7545 treatment
reducing the cell NAD+/NADH ratio, PDK inhibition decreased
intracellular aspartate (Figure S3D), and increasing the NAD+/
NADH ratio with exogenous pyruvate, duroquinone, or LbNOX
expression restored aspartate levels (Figures S3E–S3G). These
data suggest that suppressing aerobic glycolysis limits the
capacity of cells to carry out oxidation reactions important for
biomass production.
To further study how PDH activation affects metabolism, we
performed untargeted metabolomics and observed that despite
increasing PDH activity (Figures 1C and S1A), AZD7545 treat-
ment decreased intracellular citrate levels and increased intra-
cellular palmitate levels (Figures S3H and S3I). This could reflect
a metabolic state in which forcing citrate production from pyru-
vate elicits a compensatory increase in lipid synthesis, which
consumes NADPH to make NADP+, potentially as an alternative
means to regenerate oxidizing equivalents (Liu et al., 2020). We
also observed that AZD7545 treatment affected levels of many
other intracellular metabolites and that either duroquinone or
expression of LbNOX suppressed some of those changes (Fig-
ures S3J–S3M). Of note, duroquinone or LbNOX expression
restoredmany of the samemetabolites in AZD7545-treated cells
(Figure S3N). Because duroquinone and LbNOX alter NAD+/
NADH ratios via different mechanisms, the finding that both
agents similarly restored alterations to the global metabolome
caused by PDH activation argues that an effect on cell redox
state is a major consequence of increased pyruvate oxidation
and further supports the notion that a major metabolic conse-
quence of suppressing aerobic glycolysis is NAD+ depletion.PDH activation increases dependency on mitochondrial
complex I for NAD+ regeneration
Because PDK inhibition reduces the cellular NAD+/NADH ratio,
interventions that limit NAD+ regeneration are predicted to
potentiate the anti-proliferative effects of PDK inhibitors. To
test that hypothesis, we assessed the sensitivity of cancer cells
to the biguanide metformin, which limits NAD+ regeneration and
decreases NAD+/NADH ratio via inhibition of mitochondrial com-
plex I (Gui et al., 2016; Wheaton et al., 2014) (Figure 3E). The
combination of metformin and AZD7545 reduced cell prolifera-
tion more than either compound alone (Figures 3F and S4A),ells were transduced with sgPDK1 (two independently targeted lines) or sgNTC
edia with vehicle (V) or AZD7545 supplemented with or without 1 mM pyruvate
r without 1 mM pyruvate. Human CD4+ T cells were stained with CFSE before
by flow cytometry after 4 days. Representative data are shown from three
rs and analyzed as independent experiments. Stained, unstimulated cells (light
t 1mMpyruvate. Mouse T cells were stainedwith CFSE before stimulationwith
y after 2 days. Stained, unstimulated cells (light gray) that did not proliferate
7545, or 5 mM AZD7545 with 10 mM lactate (n = 4).
with or without 1 mM or 10 mM lactate as indicated (n = 3).




Figure 3. Interventions that alter NAD+ availability can modulate the antiproliferative effects of PDK inhibition
(A) Duroquinone increases NAD+ regeneration via the enzyme NAD(P)H dehydrogenase, quinone 1 (NQO1), which reduces duroquinone to durohydroquinone
using NADH as a cofactor.
(B) Proliferation rate of 143B and H1299 cells treated with vehicle (V) or AZD7545 in the absence or presence of duroquinone (20 mM for 143B and 100 mM for
H1299 cells; n = 3).
(C) Schematic illustrating the reaction catalyzed by the NADH oxidase from Lactobacillus brevis (LbNOX).
(D) Proliferation rate of 143B and H1299 cells transduced with empty vector (E.V.) or an LbNOX expression vector and treated with vehicle (V) or AZD7545.
Doxycycline (500 ng/mL) was included in all conditions (n = 3).
(E) Schematic illustrating the redox consequences of metformin treatment.
(F) Proliferation rate of 143B and H1299 cells treated with 500 mMmetformin, AZD7545 (5 mM for 143B, 3 mM for H1299 cells), and 1mMpyruvate as indicated (n = 3).
Values in (B), (D), and (F) denote means ± SD. p values were calculated by unpaired, two-tailed Student’s t test (n.s. = not significant).
ll
OPEN ACCESSArticleand AZD7545 treatment decreased the half-maximal inhibitory
concentration (IC50) of metformin by more than 30% in both
A549 and HeLa cells (Figures S4B and S4C). The anti-prolifera-
tive effect of AZD7545 and metformin was completely abolished
by pyruvate supplementation (Figures 3F and S4A–S4C), further
arguing that these drugs impair proliferation by promoting a
more-reduced NAD+/NADH ratio.Electron acceptor availability can be limiting for tumor growth
in some mouse models of cancer (Gui et al., 2016), suggesting
that inhibiting NAD+ regeneration with the combination of
AZD7545 and metformin may have a larger effect on tumor
growth than either drug alone. We found that metformin inhibited
tumor growth, as previously reported (Gui et al., 2016; Schöckel





Figure 4. PDK inhibition induces mitochondria hyperpolarization and limits NAD+ regeneration by respiration
(A) Schematic illustrating the mitochondrial electron transport chain and how FCCP (trifluoromethoxy carbonylcyanide phenylhydrazone) uncouples electron
transfer from NADH to O2 from ATP production by the FoF1-ATP synthase (complex V). DJ denotes the mitochondrial membrane potential.
(legend continued on next page)
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metformin in this model (Figure S4D).
The finding that AZD7545 treatment did not decrease tumor
growth as a single agent might be expected from the pharmaco-
kinetics of this compound, as well as the fact that AZD7545 im-
pairs, but does not prevent, cell proliferation. Three hours after
dosing, we found AZD7545 levels in tumors and in plasma that
could impair cell proliferation in culture (Figures S4E and S4F),
but the compound was not detected in plasma after 24 h (Fig-
ure S4E). This argues that more-frequent dosing of AZD7545
may bemore effective toward inhibiting tumor growth as a single
agent. Nevertheless, once-a-day dosing of AZD7545 was suffi-
cient to improve the anti-tumor effects of metformin, supporting
the notion that PDK inhibition increases dependency on
mitochondrial complex I to regenerate NAD+ and support
proliferation.
Increased mitochondrial membrane potential
downstream of pyruvate oxidation impairs NAD+
regeneration by the mitochondrial electron
transport chain
The decreased NAD+/NADH ratio observed in PDK-inhibited
cells suggests that NAD+ regeneration by mitochondrial respira-
tion is insufficient to support maximal proliferation when pyru-
vate oxidation is increased. This result is unexpected because
these cells are cultured at atmospheric oxygen and exhibit
increased oxygen consumption upon AZD7545 treatment (Fig-
ure 1D). Thus, we sought to better understand how NAD+ regen-
eration by mitochondrial respiration was impaired in PDK-in-
hibited cells because this could explain why proliferating cells
engage in aerobic glycolysis.
The oxidation-reduction reactions of the mitochondrial elec-
tron transport chain (ETC) are coupled to proton pumping from
the mitochondrial matrix into the intermembrane space to
generate an electrochemical gradient across the inner mitochon-
drial membrane and support ATP production via the FoF1-ATP
synthase (Figure 4A). This process, collectively referred to as
oxidative phosphorylation, occurs at near equilibrium, meaning
that the rate of respiration is a function of both substrate and
product availability (Brown, 1992). The shift toward a more
reduced NAD+/NADH ratio suggests NADH is more readily
available in those cells, but one possibility is that the availability
of oxygen, another major substrate for oxidative phosphoryla-(B) Mitochondrial membrane potential, as reflected by TMRE (tetramethylrhodami
AZD7545, or 5 mM AZD7545 with 500 nM FCCP.
(C) Mitochondrial membrane potential, as reflected by TMRE fluorescence, in H1
with or without 500 nMFCCP. TMRE fluorescence of 50,000 cells was quantified b
(D) The NAD+/NADH ratio of 143B and H1299 cells cultured in vehicle or AZD75
(E) The NAD+/NADH ratio of 143B and H1299 cells treated with vehicle, 5 mMAZD
(F) Aspartate levels in 143B and H1299 cells cultured in vehicle, 2 mM AZD7545,
(G) Proliferation rate of 143B and H1299 cells treated with vehicle (V) or AZD754
(H) Proliferation rate of 143B cells in which CRISPRi was used to repress PDK1 exp
or sgNTC and cultured with or without 750 nM FCCP (n = 3).
(I) Proliferation of primary mouse T cells cultured in vehicle, 5 mM AZD7545, or 5
T cells were stained with CFSE before stimulation with anti-CD3/CD28 antibodies
unstimulated cells (light gray) that did not proliferate are shown.
Values in (D)–(G) denote means ± SD. p values were calculated by unpaired, two-t
significant).tion, becomes limiting for electron transport. However, these
cells were cultured at 21% oxygen, and mitochondrial respira-
tion can function at oxygen levels as low as 0.5% (Chandel
et al., 1996; Rumsey et al., 1990). Furthermore, expression of
LbNOX, which requires oxygen as a substrate, suppressed the
anti-proliferative effect of AZD7545 (Figure 3D), arguing against
oxygen availability constraining NAD+ regeneration in PDK-in-
hibited cells.
Another possibility is that an imbalance develops between the
ability of the mitochondrial ETC to pump protons into the inter-
membrane space and the activity of processes that carry pro-
tons back across the membrane. This imbalance would be
reflected in an increased mitochondrial membrane potential
(DJ) (Figure 4A). To test that possibility, we used the cationic
dye tetramethylrhodamine ethyl ester (TMRE), which is taken
up by the mitochondria in proportion to DJ (Perry et al., 2011).
We found that PDK inhibition increases TMRE accumulation
in cancer cells (Figure 4B) and activated primary mouse T cells
(Figure S5A) and that this effect is reversed when respiration is
uncoupled from ATP production by the ionophore FCCP (trifluor-
omethoxy carbonylcyanide phenylhydrazone). FCCP allows pro-
tons to equilibrate across membranes, thus FCCP uncouples
NAD+ regeneration by the ETC fromDJ generation and prevents
use of DJ for ATP production. These data are consistent with
PDH activation increasing DJ, and increased TMRE accumula-
tion depends on the concentration of AZD7545 (Figure 4C) in a
way that matches the dose-dependent reduction in the NAD+/
NADH ratio observed upon PDK inhibition (Figures 4D and
S5B). Taken together, these data suggest that NAD+ regenera-
tion by respiration is constrained by DJ because it becomes
thermodynamically unfavorable for the mitochondrial ETC com-
plexes to pump protons across a hyperpolarized membrane.
If high DJ limits NAD+ regeneration by respiration, collapse of
DJ should restore NAD+/NADH homeostasis to cells with acti-
vated PDH. Indeed, FCCP exposure was sufficient to increase
the NAD+/NADH ratio (Figure 4E), aspartate levels (Figures 4F
and S5C), and proliferation rate (Figures 4G and S5D) of PDK-in-
hibited cells. FCCP treatment also suppressed the proliferation
defect observed in cancer cells in which PDK1 expression is
suppressed using CRISPRi (Figure 4H). Additionally, FCCP treat-
ment rescued the proliferation rates of AZD7545-treated primary
mouse T cells (Figure 4I) but not primary human T cells. These re-
sults are consistent with DJ limiting mitochondrial NAD+ne, ethyl ester) fluorescence, in 143B andH1299 cells treated with vehicle, 5 mM
299 cells that had been treated with the indicated concentration of AZD7545,
y flow cytometry and normalized to the vehicle-treated conditionwithout FCCP.
45 for 5 h (n = 4).
7545, or 5 mMAZD7545 with the indicated concentration of FCCP for 5 h (n = 4).
or 2 mM AZD7545 with 250 nM FCCP for 5 h as measured by LCMS (n = 4).
5 with or without 500 nM FCCP as indicated (n = 3).
ression. Cells were transducedwith sgPDK1 (two independently targeted lines)
mM AZD7545 with 500 nM FCCP was assessed by CFSE dye dilution. Mouse
and CFSE fluorescence was assessed by flow cytometry after 2 days. Stained,
ailed Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001; n.s. = not
Molecular Cell 81, 691–707, February 18, 2021 699
ll
OPEN ACCESS Articleregeneration. In addition, the finding that FCCP increases respi-
ration (Figure S1B) confirms that the mitochondrial ETC machin-
ery is functional and that sufficient oxygen is available to support
increased respiration in these cells. Taken together, these data
argue that mitochondrial NAD+ regeneration becomes limited
by an increase in DJ when pyruvate oxidation is increased.
NAD+ regeneration is limited by insufficient ATP
hydrolysis when PDK is inhibited
A physiological function of DJ is to support ATP synthesis
because conversion of ADP to ATP by the FoF1-ATP synthase
is coupled to dissipation of DJ (Figure 4A). Thus, insufficient
ATP turnover could limit ADP availability, limiting mitochondrial
NAD+ regeneration by oxidative phosphorylation in cells with
high pyruvate dehydrogenase activity. The observation that
FCCP treatment promotes proliferation of PDK-inhibited cells
by uncoupling mitochondrial NAD+ regeneration from ATP syn-
thesis is consistent with this model.
To better characterize potential FoF1-ATP synthase insuffi-
ciency after PDK1 inhibition, we measured intracellular ATP/
ADP ratios and found that they were unchanged by AZD7545
treatment (Figure S5E). This observation is consistent with exist-
ing notions that ATP is only made as needed because thermody-
namic constraints prevent ATP storage in cells (Bonora et al.,
2012). To test whether the FoF1-ATP synthase is unable to dissi-
pate DJ because of reduced ADP availability, we next tested
whether increasing the ATP-to-ADP conversion in cells could
reverse themetabolic and anti-proliferative effects of PDK inhibi-
tion. Promoting cellular ATP consumption stimulates mitochon-
drial respiration by increasing the demand for ADP-to-ATP con-
version (Bertholet et al., 2019; Brown, 1992). The toxin
gramicidin D is a classic way to increase ATP consumption in
cells by increasing cell membrane permeability to Na+ and K+
ions, driving increased ATP hydrolysis by Na+/K+-ATPase and
thus increasing ATP-coupled mitochondrial respiration (Buttger-
eit and Brand, 1995; Nobes et al., 1989; Vander Heiden et al.,
1999). We first confirmed that increasing cellular ATP consump-
tion with gramicidin D reversed mitochondrial membrane hyper-
polarization caused by PDK inhibition (Figure 5A). Exposing
PDK-inhibited cells to gramicidin D also resulted in a more
oxidized NAD+/NADH ratio (Figure S5F). These data are consis-
tent with gramicidin D increasing mitochondrial ATP production,
which in turn, promotes increased respiration and NAD+ regen-
eration. Of note, gramicidin D also rendered both cancer cells
and non-cancer cells more resistant to AZD7545 treatment (Fig-
ures 5B and 5C). Taken together, these data support a model in
which mitochondrial NAD+ regeneration via respiration is con-
strained by insufficient ATP synthase activity when pyruvate
oxidation is increased. These findings also suggest that cells
may engage in aerobic glycolysis under conditions in which the
demand for NAD+ regeneration exceeds the rate of ATP
consumption.
The demand for NAD+ regeneration can supersede the
requirement for ATP in proliferating cells
To begin to test whether amismatch in demand formitochondrial
NAD+ regeneration relative to demand for mitochondrial ATP
production could drive aerobic glycolysis, we used oligomycin,700 Molecular Cell 81, 691–707, February 18, 2021a selective inhibitor of the Fo-subunit of the mitochondrial FoF1-
ATP synthase. Oligomycin inhibits mitochondrial ATP production
and prevents respiration by increasing DJ (Brand and Nicholls,
2011). Culturing PDK-inhibited cells with oligomycin further in-
creases DJ beyond that observed with AZD7545 treatment
alone (Figure 5D). Therefore, oligomycin is expected to further
decrease the capacity for NAD+ regeneration via mitochondrial
respiration. We found that oligomycin potentiates the prolifera-
tion defect and the reduced NAD+/NADH ratio caused by PDK
inhibition (Figures 5E and 5F). FCCP treatment, which collapses
DJ and suppresses ATP synthesis by the mitochondrial FoF1-
ATP synthase, restores the NAD+/NADH ratio and the prolifera-
tion of cells treated with both oligomycin and AZD7545. These
data suggest that mitochondrial respiration to allowNAD+ regen-
eration can be more important than mitochondrial ATP produc-
tion in some proliferating cells, including cells that otherwise
engage in aerobic glycolysis.
The finding that uncoupling mitochondrial respiration from
ATP production can rescue proliferation of PDK-inhibited cells
argues that insufficient FoF1-ATP synthase activity can limit
NAD+ regeneration by respiration. Consistent with the demand
for NAD+ regeneration exceeding the demand for mitochondrial
ATP synthesis to support proliferation in some cells that engage
in aerobic glycolysis, we find FCCP can dose-dependently in-
crease cell proliferation in the absence of any other interventions
(Figure 6A). These data suggest that insufficient FoF1-ATP syn-
thase activity can impair NAD+ regeneration and proliferation
even in standard culture conditions with abundant oxygen and
argue that coupling between mitochondrial respiration and
ATP synthesis limits the extent to which respiration can support
NAD+ regeneration and proliferation. Thus, cells may engage in
aerobic glycolysis when the demand for NAD+ to support oxida-
tion reactions is greater than the ATP turnover rate.
Cellular NAD+ availability determines whether cells
engage in aerobic glycolysis
If increased fermentation in proliferating cells is driven by NAD+
demand in excess of ATP demand, orthogonal pathways that
promote NAD+ regeneration would be expected to suppress
the degree to which cells engage in aerobic glycolysis despite
the same redox and ATP requirements to support proliferation.
Indeed, duroquinone can suppress the rate of lactate excretion
by both cancer cells and non-transformed cells (Figures 6B
and S6A) despite similar rates of proliferation and glucose up-
take (Figures S6B and S6C). LbNOX expression did not affect
lactate excretion in the cells studied but increased pyruvate
excretion as previously reported (Titov et al., 2016) (Figure S6D),
which reflects decreased NAD+ regeneration by LDH. Addition-
ally, FCCP administration decreased lactate excretion by acti-
vated mouse T cells (Figure 6C) without changing the prolifera-
tion rate (Figure S6E). Thus, increasing NAD+ regeneration,
either by providing exogenous electron acceptors or by uncou-
pling mitochondrial respiration from ATP synthesis, suppresses
aerobic glycolysis without decreasing proliferation rate. These
data support the hypothesis that demand for NAD+ is what drives
aerobic glycolysis in these rapidly proliferating mammalian cells.
Aerobic glycolysis is linked to rapid proliferation across many





Figure 5. NAD+ regeneration by respiration is limited by the rate of mitochondrial ATP production
(A) Mitochondrial membrane potential, as reflected by TMRE fluorescence, of 143B cells cultured in vehicle, 2 mMAZD754, or 2 mMAZD754 with 5 nM gramicidin
D for 5 h.
(B) Proliferation rate of 143B, H1299, and A549 cells treated with vehicle (V) or AZD7545 in the presence or absence of 0.5 nM gramicidin D (n = 3).
(C) Proliferation rate C2C12 myoblasts or pancreatic stellate cells (PSC) cultured with vehicle (V) or AZD7545 with or without 1 nM gramicidin D (n = 3).
(D) Mitochondrial membrane potential, as reflected by TMRE fluorescence, of 143B cells cultured for 5 h with vehicle, 2 mMAZD7545, 1 nM oligomycin, and 1 mM
FCCP, as indicated.
(E) The NAD+/NADH ratio of 143B, H1299, and A549 cells in vehicle, 5 mM AZD7545, 0.5 nM oligomycin, and 1 mM FCCP, as indicated (n = 4).
(F) Proliferation rate of 143B, H1299, and A549 cells in vehicle, 5 mM AZD7545, 0.5 nM oligomycin and 1 mM FCCP, as indicated (n = 3).
Values in (B), (C), (E), and (F) denote means ± SD. p values were calculated by unpaired, two-tailed Student’s t test (n.s. = not significant).
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Figure 6. Aerobic glycolysis reflects cellular NAD+ availability
(A) The proliferation rate of 143B cells treated with FCCP, as indicated (n = 3).
(B) Relative lactate excretion of cells cultured with or without duroquinone (4 mM, 16 mM, 8 mM, and 64 mM for 143B, H1299, C2C12, and PSC cells, respectively;
n = 3).
(C) Relative lactate excretion of primary mouse T cells stimulated with anti-CD3/CD28 antibodies in the presence or absence of 250 nM FCCP for 1 day (n = 5).
(D) The relationship between ethanol production and proliferation rate in S. cerevisiae as determined by altering glucose concentration in culture medium.
(E) Relative ethanol production rate by S. cerevisiae expressing empty vector (E.V.) or LbNOX in standard medium containing 3% glucose (n = 3).
(F) Relative ethanol production rate by S. cerevisiae treated with vehicle or 2 mM FCCP in standard medium containing 3% glucose (n = 3).
Values denote means ± SD. p values were calculated by unpaired, two-tailed Student’s t test (n.s. = not significant).
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system, we considered Saccharomyces cerevisiae, a yeast in
which glucose fermentation to ethanol accompanies rapid prolif-
eration, even in aerobic conditions (De Deken, 1966). We
confirmed that glucose availability can affect the proliferation
rate and ethanol production in batch cultures of S. cerevisiae,
even in aerated cultures (Figures S6F and S6G). We found a
linear relationship between proliferation and fermentation rates
(Figure 6D), confirming that aerobic glycolysis is correlated
with proliferation in this yeast. To test whether fermentation is
driven by the increased NAD+ demand of rapid proliferation in
S. cerevisiae, we assessed the effect of LbNOX expression on
both proliferation and aerobic glycolysis. LbNOX expression
decreased ethanol production without altering the proliferation
rate (Figures 6E and S6H), arguing that demand for NAD+ also
promotes aerobic glycolysis in this organism, consistent with
previous reports (Vemuri et al., 2007).
To test the hypothesis that an elevated mitochondrial mem-
brane potential limits the ability of respiration to support NAD+
regeneration in S. cerevisiae, we also assessed the effect of
FCCP on both proliferation and aerobic glycolysis. In agreement
with our hypothesis, we saw that FCCP decreased the ethanol
production rate without altering proliferation (Figures 6F and
S6I). The fact that FCCP reduces mitochondrial ATP production,
as well as fermentation rates, argues that ATP synthase in rapidly702 Molecular Cell 81, 691–707, February 18, 2021proliferating yeast is governed by the same limitations as rapidly
proliferating mammalian cells. When coupled with the finding
that the link between rapid proliferation and aerobic glycolysis
is broken if cells are allowed alternative pathways of NAD+
regeneration, these observations suggest that demand for
NAD+ in excess of demand for ATP drives aerobic glycolysis in
diverse organisms across kingdoms of life, regardless of
whether lactate or ethanol are produced as the fermentation
product.
DISCUSSION
Aerobic glycolysis is observed across species ranging from pro-
karyotes to specific mammalian cell types, yet a generalizable
explanation for this phenotype has been lacking. The data from
this study suggest that aerobic glycolysis reflects a metabolic
state in which the demand for NAD+ exceeds the demand for
ATP to support cell function. Oxidation of pyruvate, rather than
fermentation, increases the demand for mitochondrial respira-
tion to regenerate NAD+. However, because mitochondrial elec-
tron transport is coupled to mitochondrial ATP synthesis, when
the demand for NAD+ exceeds the demand for ATP, insufficient
ATP synthase activity leads to increased DJ and constrains
further increases in mitochondrial respiration. Thus, ATP hydro-
lysis, which supplies ADP as substrate for mitochondrial ATP
ll
OPEN ACCESSArticlesynthesis and dissipates DJ produced by the mitochondrial
ETC, imposes an upper limit on the rate of mitochondrial NAD+
regeneration, regardless of oxygen availability. Therefore, if the
requirement for NAD+ to fuel oxidation reactions is greater than
the rate of ATP turnover, pyruvate oxidation is limited and the
more-reduced NAD+/NADH ratio promotes fermentation, even
if oxygen is present. These findings are consistent with a theoret-
ical prediction that NADH generation could impair biomass syn-
thesis in aerobic conditions if proliferation is fast enough (Fer-
nandez-de-Cossio-Diaz and Vazquez, 2017).
Although the reactions that regenerate NAD+ do not directly
provide biomass to cells, this cofactor is needed to catabolize
reduced nutrients, including sugars and lipids, and to synthesize
oxidized macromolecules, such as nucleotides and amino acids
(Hosios and Vander Heiden, 2018). Previous work has identified
aspartate synthesis as a major NAD+ demand (Birsoy et al.,
2015; Garcia-Bermudez et al., 2018; Gui et al., 2016; Sullivan
et al., 2015; Sullivan et al., 2018), and cells require NAD+ to sup-
port additional cellular processes, including serine and folate
synthesis (Baksh et al., 2020; Bao et al., 2016; Diehl et al.,
2019), histone deacetylation by sirtuins, maintenance of calcium
homeostasis, and poly(ADP-ribose) polymerase activity (Cantó
et al., 2015; Ying, 2008). Electron acceptor availability can
restrict cell proliferation, and the NAD+/NADH ratio has been
found to correlate with tumor growth in vivo (Gui et al., 2016).
Non-proliferating cells with high anabolic demands, such as
mammalian retina pigmented epithelial cells, also require
NAD+, and retinal toxicity has proven to be a liability for drugs
that target NAD+ synthesis (Zabka et al., 2015). Lastly, forced py-
ruvate oxidation induces NAD+ deficiency in epidermal stem
cells, which can impair biomass production (Baksh et al.,
2020), further arguing that demand for NAD+ can be high in
some cells.
Several explanations have been proposed for the Warburg ef-
fect; many of which consider how inefficient ATP production by
aerobic glycolysis is sufficient to support the high ATP demands
of proliferation. The finding that uncoupling respiration from ATP
production allows increased pyruvate oxidation and continued
proliferation, even in the presence of oligomycin, argues strongly
that the requirement for NAD+ can be greater than the require-
ment for ATP in at least some proliferating cells. Furthermore,
the observation that increasing ATP consumption also allows
proliferation, despite increased pyruvate oxidation, suggests
insufficient ATP turnover can limit mitochondria respiration in
cells and that aerobic glycolysis may, therefore, reflect a state
of high NAD+ demand and excess ATP. The idea that ATP hydro-
lysis, rather than ATP synthesis, could be limiting for cancer cell
metabolism has historical support (Racker, 1972; Scholnick
et al., 1973), although this possibility is not considered by most
studies. Nevertheless, it has been reported that some prolifer-
ating cells engage in futile metabolic cycles that consume ATP,
such as fatty acid synthesis and oxidation (Yao et al., 2016),
increased protein turnover (Zhang et al., 2014b), or the creatine
shuttle (Kurmi et al., 2018) for unclear reasons. These futile cy-
cles may promote ATP consumption to support oxidized
biomass synthesis and could explain why increased ATP turn-
over involving ENTPD5 can promote the proliferation of PTEN-
null cancers or why increasing the ATP/AMP ratio can result intumor regression (Fang et al., 2010; Naguib et al., 2018). The
mechanism by which ATP consumption promotes proliferation
in those contexts remains unexplained, but a model in which
excess ATP constrains NAD+ regeneration by respiration is
consistent with increasing ATP consumption enabling
proliferation.
Although demand for NAD+ that exceeds demand for ATP can
explain why some cells engage in fermentation, rather than
oxidative metabolism, this model does not explain why
increased glucose uptake and glycolysis are also often associ-
ated with proliferation. Fermentation is redox neutral and does
not net regenerate NAD+. In fact, the only known output of
fermentation is ATP, and if excess ATP limits net NAD+ regener-
ation to promote fermentation, why glucose metabolism is
increased during rapid proliferation remains unexplained. Never-
theless, a model in which aerobic glycolysis reflects a metabolic
state in which the requirement for NAD+ supersedes the demand
for ATP is consistent with the reality of this metabolic phenotype,
which is best characterized by a relative increase in fermenta-
tion, rather than a complete switch from mitochondrial respira-
tion to glycolysis. It also fits with the broad association between
aerobic glycolysis and proliferation (Diaz-Ruiz et al., 2011), the
link between this phenotype and nucleotide synthesis (Lunt
et al., 2015; Wang et al., 1976), the continued dependence of
most proliferating cells on respiration (Howell and Sager, 1979;
Tan et al., 2015; Weinberg et al., 2010; Wheaton et al., 2014;
Zhang et al., 2014a), and the fact that reversing aerobic glycol-
ysis slows, rather than stops, proliferation.
Different species of yeast diverge in their response to glucose
in terms of their propensity to ferment carbon (De Deken, 1966),
and organisms that proliferate rapidly without engaging in aer-
obic glycolysis may have evolved mechanisms to prevent a
mismatch in the demand for NAD+ and ATP. Of note, regulated
uncoupling of mitochondrial respiration from ATP synthesis is
important for thermoregulation, and these same processes
could also facilitate rapid proliferation (Li et al., 2020). Although
mammalian uncoupling proteins have limited tissue expression
and are tightly regulated, these proteins are overexpressed in
some cancers (Kawashima et al., 2020; Robbins and Zhao,
2011; Valle et al., 2010). Expression of uncoupling proteins,
as well as other means to uncouple mitochondrial respiration
(Bertholet et al., 2019), may support NAD+ regeneration in con-
texts in which NAD+ demand exceeds the demand for ATP. For
example, lymphocytes can proliferate faster than most other
mammalian cells and may use such an adaptive program to
support proliferation, potentially explaining why we observe
variability in whether FCCP-mediated mitochondrial uncou-
pling can enhance T cell proliferation. However, the fact that
maintaining a high ATP/ADP ratio is essential for cell survival
may explain why nutrient oxidation remains tightly coupled in
ATP production in most cells and leads to aerobic glycolysis
being engaged when the demand for NAD+ exceeds the de-
mand for ATP.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture experiments
Established cell lines (143B, ATCC CRL-8303; A549, ATCC CCL-185; C2C12, ATCC CRL-1772; ATCC CRL-5803; H1299, ATCC
CRL-5803; HeLa, ATCC CCL-2; A172, ATCC CRL-1620; MDA-MB-231, ATCC HTB-26) were maintained in DMEM (Corning,
10-013-CV) supplemented with 10% fetal bovine serum (FBS). For all experiments, cells were washed three times in phosphate
buffered saline (PBS), and then cultured in DMEM without pyruvate (Corning, 10-017-CV) with 10% dialyzed FBS, supplemented
with the indicated treatment condition. The reagents used for the cell culture experiments are as follows: AZD7545 (Selleck Chem-
icals, s7517), sodium pyruvate (Sigma, P2256), sodium L-lactate (Sigma, L7022), duroquinone (Sigma, D223204), metformin hydro-
chloride (Sigma, PHR1084), FCCP (carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, also referred to as trifluoromethoxy car-
bonylcyanide phenylhydrazone) (Sigma, C2920), oligomycin A (Sigma, 75351), gramicidin from Bacillus aneurinolyticus (Bacillus
brevis) (Sigma, G5002). All cells were cultured at 37C with 5% CO2.
CRISPRi/Cas9-mediated repression of PDK1
PDK1 expression was suppressed using CRISPR interference (CRISPRi)-mediated transcriptional repression. A CRISPRi library
(Horlbeck et al., 2016) was used to design sgRNA human targeting PDK1 (Guide 1: F 50GCTCACGTACCACTCGGCAG 30; Guide
2: F 50GACGTCCCTCACGTACCACT 30) or a non-targeting control (NTC; F 50GGGAACCACATGGAATTCGA 30). The sgRNA
were cloned into a modified LentiCRISPRv2 plasmid, in which Cas9 was mutated to nuclease-dead Cas9 and fused to repressiveMolecular Cell 81, 691–707.e1–e6, February 18, 2021 e2
ll
OPEN ACCESS Articlechromatinmodifier domain KRAB (Kr€uppel-associated box) domain of Kox1 (dCAS9-KRAB) (Gilbert et al., 2013). A pooled population
of stable knockdown cell lines were generated and maintained in 5 mM/mL blasticidin.
Generation of LbNOX-expressing cells
LbNOX-FLAG cDNA was cloned from pUC57-LbNOX using the primers 50-GGGGACAAGTTTGTACAAAAAAGCAGGCATGAAGGT-
CACCGTGGTC-30 and 50-GGGGACCACTTTGTACAAGAAAGCTGGGTTTACTTGTCATCGTCATCCTTGTAATC-30. pUC57-LbNOX
was a gift from Vamsi Mootha (Addgene, 75285). The PCR product was subsequently cloned into pInducer20 using LR Clonase II
Plus (ThermoFisher, 12538120). pInducer20 was a gift from Stephen Elledge (Addgene, 44012). A549, 143B, and H1299 cells
were transduced with lentivirus containing pInducer20-LbNOX-FLAG or pInducer20-E.V. and 10ug/mL polybrene (Millipore, TR-
1003-G). The infected cells were selected in 1 mg/mL G418 (VWR, G5005). For proliferation experiments done with these cell lines,
all conditions were supplemented with 500 ng/mL doxycycline.
Pancreatic stellate cell (PSC) isolation
PSCs were isolated from b-actin-GFPmice (The Jackson Laboratory, 006567) in which 3 mL of 1.3 mg/mL cold collagenase P (Sigma,
11213865001) and 0.01 mg/mL DNase (Sigma, D5025) in GBSS (Sigma, G9779) were injected into the pancreas. The tissue was then
placed into 2 mL of 1.3 mg/mL collagenase P solution on ice. Cells were then placed in a 37Cwater bath for 15minutes. The digested
pancreaswas filtered through a 250 mmstrainer andwashedwithGBSSwith 0.3%BSA.A gradientwas created by suspending the cells
in Nycodenz (VWR, 100356-726) and layering in GBSS with 0.3% BSA. Cells were then centrifuged at 13003 g for 20 minutes at 4C.
The layer containingPSCswas removed, filtered through a 70mmstrainer, washed inGBSSwith 0.3%BSA, and plated for cell culture in
DMEM (Corning, 10-013-CV) with 10% FBS and penicillin-streptomycin (P/S). Post-isolation, PSCs were immortalized with TERT and
LargeT Antigen overexpression and cultured DMEM (Corning, 10-013-CV) supplemented with 10% FBS.
T cell isolation and culture
Primary human CD4+ T cells were isolated from peripheral blood by density gradient centrifugation over Lympholyte-H (Cedarlane
Laboratories) and negative selection using the Dynabeads Untouched Human CD4 T Cells kit (Thermo Fisher, 11346D) according to
the manufacturer’s instructions. Purity was assessed by flow cytometry for CD3 and CD4 and routinely found to be R 95%. Cells
were activated using Dynabeads Human T-Activator CD3/CD28 beads (Invitrogen) according to the manufacturer’s instructions
and cultured in RPMI supplemented with 10% FBS and 30 U/mL recombinant human IL-2 (PeproTech, 200-02) at 37C in 5%
CO2. Primary mouse T cells were isolated from the spleens and lymph nodes of C57BL/6J mice using a Pan-T cell isolation kit
(Miltenyl Biotec, 130-095-130). Isolated murine T cells were activated on plates coated with anti-CD3e (BD Pharmigen, 553057)
and anti-CD28 (BD PharMingen, 553294) antibodies and cultured in RPMI with 10% FBS (non-dialyzed), 1% P/S, 1x NEAA culture
supplement (Thermo Fischer Scientific, 11140050), and 50 mM b-mercaptoethanol.
Tumor growth in mice
Two million A549 or one million 143B cells were injected into the flanks of 4-6 week old, male NU/NUmice (Charles River Laboratories,
088). A caliper was used tomeasure flank tumor volume in two dimensions and volumewas calculated using the equation V = (p/6)(L3
W2). Lengthwas defined to be the longer of the two dimensionsmeasured. For the A549 xenografts, the tumorswere permitted to reach
a size of 50 mm3, after which the animals were randomly assigned to an experimental group and the treatment regimen was initiated.
Metformin (500mg/kg) and AZD7545 (45mg/kg)were both administered oncedaily by oral gavage, with a vehicle ofwater and 0.5% (w/
w) methocel/0.1% polysorbate 80 respectively. All animal experiments were approved by the MIT Committee on Animal Care.
METHOD DETAILS
Proliferation rates
Cells were plated in replicate six-well plates in 2 mL at an initial seeding density of 20,000 cells per well for all cells except for MDA-MB-
231, which were seeded at 40,000 cells per well. Cells were permitted to settle overnight and one six-well dishwas counted to calculate
the starting cell number at the initiation of the experiment. For all remaining dishes, cells were washed three times with PBS and 4mL of
treatmentmediawas added to eachwell. After 48 hours, cells werewashed again three timeswith PBS and 4mLof the treatmentmedia
was replenished. Four days after the initial treatment, cells were counted to obtain the final cell counts for the experiment. Counts were
done using a Cellometer Auto T4 Plus Cell Counter (NexcelcomBioscience) or by sulforhodamine B (SRB) assay. For cell quantification
by SRB, cells were fixed by adding trichloroacetic acid to culture media (final concentration of 3.3%) and incubated 4C for at least one
hour. Fixed cells were washed with deionized water and then stained with 0.057% SRB in 1% acetic acid for 30 min. Following three
washes with 1% acetic acid, plates were air-dried at room temperature. To solubilize the SRB dye, 1 mL of 10 mM Tris (pH 10.5) was
added per well, and absorbance was measured at 510 nm using a microplate reader (Tecan Infinite, M200Pro).
T cell proliferation assay
Proliferation of primary human CD4+ T cell and primary mouse T cell proliferation was assessed by dye dilution. Freshly isolated cells
were incubated at 1 3 107 cells/mL in PBS with 0.5% dialyzed FBS supplemented with 5 mM carboxyfluorescein succinimidyl estere3 Molecular Cell 81, 691–707.e1–e6, February 18, 2021
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quenched with ice-cold complete media and washed cells were resuspended in RPMI supplemented with 10% dialyzed FBS and
the indicated treatment condition before activation. For human CD4+ T cells, cells were expanded in fresh media containing the indi-
cated treatment condition and CFSE fluorescence was thenmeasured by flow cytometry after another 2 days. Primary murine T cells
were expanded in freshmedia containing the indicated treatment condition for 2 days, andCFSE fluorescencewas thenmeasured by
flow cytometry.
Flow cytometry of T cells
CD3/CD28 Dynabeads were removed from stimulated primary human CD4+ T cells using a DynaMag-2magnet (Invitrogen). For anti-
body staining, cells were incubated for 30minutes at 4C in PBSwith a fluorochrome-conjugated antibody (mousemonoclonal APC-
conjugated anti-CD69 (BioLegend, 310909); mouse monoclonal PE-conjugated anti-CD25 (PharMingen, 30795X) as indicated). For
antibody staining or fluorescent dye dilution, cells were analyzed using a FACSCanto II, FACSCalibur or LSR Fortessa (BD Biosci-
ences) flow cytometer. For mouse T cell antibody staining, cells were incubated for 30 minutes at 4C in PBS containing 2% fetal
bovine serum with eFluor780 viability dye (eBioscience, 65-0865-18) and fluorochrome-conjugated antibodies: mouse monoclonal
PE-CF594-conjugated anti-CD45 (BDHorizon 562420) and eFluor450-conjugated anti-CD3e (Thermo Fisher Scientific, 48-0032-80);
TMRE staining (Thermo Fisher Scientific, T669) was performed at room temperature in FluoroBrite DMEM (Thermo Fischer Scientific,
A1896701) supplemented with dialyzed FBS. Stained cells were analyzed using a LSR-II or LSR Fortessa (BD Biosciences) flow
cytometer. Data processing (including proliferation analysis) was conducted using FlowJo V10.6.1.
LCMS metabolite measurement
Metabolites weremeasured by LCMS on a QExactive bench top orbitrapmass spectrometer equipped with an IonMax source and a
HESI II probe, which was coupled to a Dionex UltiMate 3000 HPLC system (Thermo Fisher Scientific, San Jose, CA). External mass
calibration was performed using the standard calibration mixture every 7 days. For each sample, 4 mL of each sample was injected
onto a SeQuant ZIC-pHILIC 1503 2.1mmanalytical column equippedwith a 2.13 20mmguard column (both 5mmparticle size;
EMDMillipore). Buffer A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide; Buffer B was acetonitrile. The column oven
and autosampler tray were held at 25C and 4C, respectively. The chromatographic gradient was run at a flow rate of 0.150 mL/min
as follows: 0-20 min: linear gradient from 80%–20% B; 20-20.5 min: linear gradient form 20%–80% B; 20.5-28 min: hold at 80% B.
The mass spectrometer was operated in full-scan, polarity-switching mode, with the spray voltage set to 3.0 kV, the heated capillary
held at 275C, and the HESI probe held at 350C. The sheath gas flow was set to 40 units, the auxiliary gas flow was set to 15 units,
and the sweep gas flow was set to 1 unit. MS data acquisition was performed in a range of m/z = 70–1000, with the resolution set at
70,000, the AGC target at 13 106, and the maximum injection time (Max IT) at 20 msec. For detection of 13C-labeled citrate, targeted
selected ion monitoring (tSIM) scans in negative mode centered on 194.1985 was included. The isolation window was set at 8.0 m/z.
For all tSIM scans, the resolution was set at 70,000, the AGC target was 1105, and the max IT was 250 ms.
Relative quantitation of polar metabolites was performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5 ppm
mass tolerance and referencing an in-house library of chemical standards.
GCMS metabolite measurement
Gas-chromatography coupled to mass spectrometry (GCMS) analysis was done as described previously (Lewis et al., 2014).
Dried metabolite samples were derivatized with 20 mL of methoxamine (MOX) reagent (ThermoFisher, TS-45950) and 25 mL of
N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-butyldimethylchlorosilane (Sigma, 375934). Following derivatiza-
tion, samples were analyzed using a DB-35MS column (30m3 0.25mm i.d.3 0.25 mm, Agilent J&WScientific) in an Agilent 7890 gas
chromatograph (GC) coupled to an Agilent 5975Cmass spectrometer (MS). Data were corrected for natural isotope abundance using
in-house algorithms as in Lewis et al. (2014).
Dynamic stable-isotope labeling experiments
Cells were plated in six-well plates at a seeding density of 150,000 cells per well and cultured overnight. Prior to the initiation of the
experiment, cells were washed three times with PBS, and then cultured in 1.5 mL media containing 5mM glucose and the indicated
treatment condition prior to tracing glucose fate. To assess glucose fate, 30 mL of a 1M [U-13C6]glucose solution was added to a final
concentration of 20 mM for the indicated time (ranging from 2 to 12 minutes). At each time point wells were washed as quickly as
possible with ice-cold blood bank saline and lysed on the dish with 300 mL of ice-cold 80% HPLC grade methanol in HPLC grade
water. Samples were scraped, collected into Eppendorf tubes, and vortexed for 10 minutes at 4C. Samples were centrifuged at
21,000 3 g for 10 minutes at 4C to precipitate protein. 50 mL of each sample was collected for immediate analysis by LCMS, or
the supernatant was dried down under nitrogen gas for subsequent analysis by GCMS.
Oxygen consumption
Oxygen consumption rates (OCR) wasmeasured using an Agilent Seahorse Bioscience Extracellular Flux Analyzer (XF24) using stan-
dard methods. Briefly, cells were plated at 50,000 cells per well in Seahorse Bioscience 24-well plates in 50 mL of DMEM without
pyruvate (Corning, 10-017-CV) supplemented with 10% dialyzed fetal bovine serum. An additional 500mL of media was addedMolecular Cell 81, 691–707.e1–e6, February 18, 2021 e4
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with the indicated treatment. Five hours later, OCR measurements were made every 6 minutes, and injections of pyruvate at 16 mi-
nutes, FCCP (Sigma, C2920) at 32 minutes, and rotenone (Sigma, R8875; 2 mM) and antimycin (Sigma, A8674; 2 mM) at 48 minutes.
Basal OCR was calculated by subtracting residual OCR following the addition of rotenone and antimycin from the initial OCR
measurements.
Glucose/lactate excretion index
Medium was collected from cells cultured in vehicle or 0.25 mM AZD7545 for 48 hours. Glucose and lactate concentrations were
measured on a YSI-2900 Biochemistry Analyzer as described previously, and rate of lactate excretion into media was normalized
to consumption of glucose (Hosios et al., 2016).
Lactate and pyruvate excretion
Medium was collected from 143B cells cultured in pyruvate-free DMEM treated with vehicle or 200mM duroquinone for 48 hours, or
mediumwas collected from143B cells cultured in pyruvate-free DMEMexpressing empty vector or LbNOX for 48 hours. Extracellular
pyruvate and lactate were measuring using GCMS, using a labeled internal standard (Cambridge Isotopes, CLM-1579-PK), and the
excretion was normalized to the proliferation rate to calculate the rate per unit growth. For H1299, PSC, andC2C12 cells, extracellular
lactate wasmeasured using a YSI-2900 Biochemistry Analyzer after treatment with the indicated amount of duroquinone for 48 hours
in pyruvate-free DMEM. Lactate excretion in primary mouse T cells was measured using a YSI-2900 Biochemistry Analyzer after 24
hours of stimulation using anti-CD3e (BD Biosciences, 553057) and anti-CD28 (BD Biosciences, 553294) antibodies and cultured in
RPMI with 10% FBS, 1% P/S, 1x NEAA culture supplement (Thermo Fischer Scientific, 11140050), and 50mM b-mercaptoethanol.
Lactate excretion was normalized to proliferation rate as assessed by counting the cells using a Cellometer Auto T4 Plus Cell Counter
(Nexcelcom Bioscience).
Western blot analysis
Cells washed with ice-cold PBS, and scraped into cold RIPA buffer containing cOmplete Mini protease inhibitor (Roche,
11836170001) and PhosStop Phosphatase Inhibitor Cocktail Tablets (Roche, 04906845001). Protein concentration was calculated
using the BCA Protein Assay (Pierce, 23225) with BSA as a standard. Lysates were resolved by SDS-PAGE and proteins were trans-
ferred onto nitrocellulose membranes using the iBlot2 Dry Blotting System (Thermo Fisher, IB21001, IB23001). Protein was detected
with the primary antibodies anti-Pyruvate Dehydrogenase E1-alpha subunit (phospho S293) (Abcam, ab92696), anti-PDK1
(Cell Signaling Technologies, 3062S), anti-FLAG (Sigma, F1804) and anti-Vinculin (Sigma, V9131). The secondary antibodies used
were IR680LT dye conjugated anti-rabbit IgG (Li-Cor Biosciences, 925-68021), IRDye 800CW conjugated anti-mouse IgG (Li-Cor
Biosciences, 925-32210), HRP-conjugated anti-rabbit IgG (Millipore, 12–348), and HRP-conjugated anti-mouse IgG (Millipore,
12-349).
NAD+/NADH measurements
Cells were seeded at 20,000 cells per well in six-well plates and permitted to adhere overnight. Cells were then washed three times
in PBS and incubated in 4 mL of the indicated treatment media for 5 hours prior to rapidly washing three times in 4C PBS and
extraction in 100mL of ice-cold lysis buffer (1% dodecyltrimethylammonium bromide [DTAB] in 0.2 N of NaOH diluted 1:1 with
PBS), then snap-frozen in liquid nitrogen and frozen at 80C. The NAD+/NADH ratio was measured using an NAD/NADH-Glo
Assay kit (Promega, G9072) according to a modified protocol as described previously (Gui et al., 2016). Briefly, to measure
NAD+, 20 mL of lysate was transferred to PCR and diluted with 20 mL of lysis buffer and 20 mL 0.4 N HCl, and subsequently incu-
bated at 60C for 15minutes. For NADHmeasurement, 20 mL of freshly thawed lysate was transferred to PCR tubes and incubated
at 75C for 30 minutes. The acidic conditions permit for selective degradation of NADH, while the basic conditions degrade NAD+.
Following the incubation, samples were spun on a bench-top centrifuge and quenched with 20 mL neutralizing solution. The
neutralizing solution consisted of 0.5 M Tris base for NAD+ samples and 0.25 M Tris in 0.2 N HCl for the NADH samples. The in-
structions in the Promega G9072 technical manual were then followed to measure NAD+ and NADH levels using a luminometer
(Tecan Infinite, M200Pro).
ATP/ADP measurements
Cells were seeded at 5,000 cells per well in 96-well plates and permitted to adhere overnight. Cells were then washed one time
with PBS and incubated in 200 mL of the indicated treatment media for 24 hours. ATP and ADP measurements were made
using a luciferase-based assay (Sigma, MAK135) based on manufacturer’s instructions. Luminescence was measured using a
luminometer (Tecan Infinite, M200Pro).
Yeast proliferation and metabolite analysis
In studies comparing the effects of LbNOX on ethanol production, CEN.PK 5D (MATa ura3-52 HIS3, LEU2 TRP1 MAL2-8c SUC2)
expressing p416-TEF-lbNOX or p416-TEF (empty vector) were grown in log phase in YPD (3% glucose) at 30C. At OD = 0.8,
supernatant was collected and analyzed for ethanol content using an Ethanol Assay Kit (Sigma, MAK076). Rate of ethanol productione5 Molecular Cell 81, 691–707.e1–e6, February 18, 2021
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cultured in YPD (3% glucose) at 30C in the indicated amount of FCCP.
Mitochondrial membrane potential measurement
Mitochondrial membrane potential was assessed using the TMRE (tetramethylrhodamine, ethyl ester) assay kit (Abcam, ab113852) in
nonquench mode. The concentration of TMRE in nonquench mode was determined empirically (Perry et al., 2011). Cells were plated
in 6 well dishes at a plating density of 150,000 cells per well and incubated in media containing the indicated concentration of vehicle
AZD7545, 500 nM FCCP, 1 nM oligomycin, and/or 5nM gramicidin D. The cells were then treated with TMRE for 30 minutes,
trypsinized, washed with PBS, and resuspended in GIBCO FluoroBrite DMEM (Thermo Fisher Scientific, A1896701) containing
the same concentration of TMRE supplemented with 10% dialyzed FBS. TMRE fluorescence was measured on a BD LSR II flow
cytometer.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details pertaining to all statistical analyses can be found in the figure legends.Molecular Cell 81, 691–707.e1–e6, February 18, 2021 e6
